CSPC Megalith Biopharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jun 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,357,472) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,471,037) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Homogenous antibody drug conjugates via enzymatic methods (US 10,639,291) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 23, 2026
- Oct 20 US 12,767,713 ANTI-SIGLEC15 Antibody and Use Thereof
- Sep 22 US 12,741,032 ANTI-CLDN182 Antibody, Drug Conjugate, and Preparation Method Therefor and Use Thereof
- Sep 1 US 12,723,100 NECTIN-4 Antibodies and Uses Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,357,472 | Homogenous antibody drug conjugates via enzymatic methods In force · USPTO record | In force | USPTO record | |
| US 10,471,037 | Homogenous antibody drug conjugates via enzymatic methods In force · USPTO record | In force | USPTO record | |
| US 10,639,291 | Homogenous antibody drug conjugates via enzymatic methods In force · USPTO record | In force | USPTO record | |
| US 11,285,128 | Homogenous antibody drug conjugates via enzymatic methods In force · USPTO record | In force | USPTO record | |
| US 11,407,828 | Anti-CLauDiN 18 antibodies and methods of use thereof In force · USPTO record | In force | USPTO record | |
| US 12,679,890 | Anti-Claudin 18 Antibodies and Methods of Use Thereof In force · Low confidence | In force | Low confidence | |
| US 12,458,818 | Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same In force · USPTO record | In force | USPTO record | |
| US 12,559,534 | Modified IL-2 Proteins, Peg Conjugates, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,723,100 | NECTIN-4 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,741,032 | ANTI-CLDN182 Antibody, Drug Conjugate, and Preparation Method Therefor and Use Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded